JNJ-26481585 primes rhabdomyosarcoma cells for chemotherapeutics by engaging the mitochondrial pathway of apoptosis

Oncotarget

Volumn 6, Issue 35, 2015, Pages 37836-37851

  Heinicke, Ulrike ^a   Kupka, Johanna ^a   Fulda, Simone ^a,b  

^a GOETHE UNIVERSITY   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Apoptosis; Cell death; HDACI; Mitochondria; Rhabdomyosarcoma

Indexed keywords

BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; QUISINOSTAT; VINCRISTINE; ANTINEOPLASTIC ANTIBIOTIC; BAK1 PROTEIN, HUMAN; BAX PROTEIN, HUMAN; HYDROXAMIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CELL VIABILITY; CHORIOALLANTOIS; CLONOGENESIS; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; EMBRYO; ENZYME ACTIVATION; FLOW CYTOMETRY; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MITOCHONDRION; MOUSE; NONHUMAN; PROTEIN CLEAVAGE; RHABDOMYOSARCOMA; TUMOR XENOGRAFT; ANIMAL; CELL PROLIFERATION; CHICK EMBRYO; DRUG EFFECTS; METABOLISM; PATHOLOGY; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CELL PROLIFERATION; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; DOXORUBICIN; DRUG SYNERGISM; HUMANS; HYDROXAMIC ACIDS; MICE; MITOCHONDRIA; PROTO-ONCOGENE PROTEINS C-BCL-2; RHABDOMYOSARCOMA; TUMOR CELLS, CULTURED;

EID: 84947802676     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6097     Document Type: Article

References (29)

1. Dagher R and Helman L. Rhabdomyosarcoma: an overview. Oncologist. 1999; 4: 34-44.
2. Hayes-Jordan A and Andrassy R. Rhabdomyosarcoma in children. Curr Opin Pediatr. 2009; 21: 373-378.
3. Dantonello TM, Int-Veen C, Harms D, Leuschner I, Schmidt BF, Herbst M, Juergens H, Scheel-Walter HG, Bielack SS, Klingebiel T, Dickerhoff R, Kirsch S, Brecht I, et al. Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults. J Clin Oncol. 2009; 27: 1446-1455.
4. Ellis L, Atadja PW and Johnstone RW. Epigenetics in cancer: targeting chromatin modifications. Mol Cancer Ther. 2009; 8: 1409-1420.
5. Cress WD and Seto E. Histone deacetylases, transcriptional control, and cancer. J Cell Physiol. 2000; 184: 1-16.
6. Timmermann S, Lehrmann H, Polesskaya A and Harel-Bellan A. Histone acetylation and disease. Cell Mol Life Sci. 2001; 58: 728-736.
7. Bolden JE, Peart MJ and Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006; 5: 769-784.
8. Matthews GM, Newbold A and Johnstone RW. Intrinsic and extrinsic apoptotic pathway signaling as determinants of histone deacetylase inhibitor antitumor activity. Adv Cancer Res. 2012; 116: 165-197.
9. Fulda S, Galluzzi L and Kroemer G. Targeting mitochondria for cancer therapy. Nat Rev Drug Discov. 2010; 9: 447-464.
10. Adams JM and Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene. 2007; 26: 1324-1337.
11. Arts J, King P, Marien A, Floren W, Belien A, Janssen L, Pilatte I, Roux B, Decrane L, Gilissen R, Hickson I, Vreys V, Cox E, et al. JNJ-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity. Clin Cancer Res. 2009; 15: 6841-6851.
12. Venugopal B, Baird R, Kristeleit RS, Plummer R, Cowan R, Stewart A, Fourneau N, Hellemans P, Elsayed Y, McClue S, Smit JW, Forslund A, Phelps C, et al. A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors. Clin Cancer Res. 2013; 19: 4262-4272.
13. Deleu S, Lemaire M, Arts J, Menu E, Van Valckenborgh E, King P, Vande Broek I, De Raeve H, Van Camp B, Croucher P and Vanderkerken K. The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models. Leukemia. 2009; 23: 1894-1903.
14. Carol H, Gorlick R, Kolb EA, Morton CL, Manesh DM, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak A, Hickson I, Lyalin D, Kurmasheva RT, et al. Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 2014; 61: 245-252.
15. Weiss A, Gill J, Goldberg J, Lagmay J, Spraker-Perlman H, Venkatramani R and Reed D. Advances in therapy for pediatric sarcomas. Curr Oncol Rep. 2014; 16: 395.
16. Vogler M, Walczak H, Stadel D, Haas TL, Genze F, Jovanovic M, Bhanot U, Hasel C, Moller P, Gschwend JE, Simmet T, Debatin KM and Fulda S. Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma. Cancer Res. 2009; 69: 2425-2434.
17. Stupack DG, Teitz T, Potter MD, Mikolon D, Houghton PJ, Kidd VJ, Lahti JM and Cheresh DA. Potentiation of neuroblastoma metastasis by loss of caspase-8. Nature. 2006; 439: 95-99.
18. Graab U, Hahn H and Fulda S. Identification of a novel synthetic lethality of combined inhibition of hedgehog and PI3K signaling in rhabdomyosarcoma. Oncotarget. 2015; 6: 8722-8735.
19. Hugle M, Belz K and Fulda S. Identification of synthetic lethality of PLK1 inhibition and microtubule-destabilizing drugs. Cell Death Differ. 2015; May 29 [E-pub ahead of print].
20. Desagher S, Osen-Sand A, Nichols A, Eskes R, Montessuit S, Lauper S, Maundrell K, Antonsson B and Martinou JC. Bid-induced conformational change of Bax is responsible for mitochondrial cytochrome c release during apoptosis. J Cell Biol. 1999; 144: 891-901.
21. Griffiths GJ, Dubrez L, Morgan CP, Jones NA, Whitehouse J, Corfe BM, Dive C and Hickman JA. Cell damageinduced conformational changes of the pro-apoptotic protein Bak in vivo precede the onset of apoptosis. J Cell Biol. 1999; 144: 903-914.
22. Chen X, Stewart E, Shelat AA, Qu C, Bahrami A, Hatley M, Wu G, Bradley C, McEvoy J, Pappo A, Spunt S, Valentine MB, Valentine V, et al. Targeting oxidative stress in embryonal rhabdomyosarcoma. Cancer Cell. 2013; 24: 710-724.
23. Witt O, Milde T, Deubzer HE, Oehme I, Witt R, Kulozik A, Eisenmenger A, Abel U and Karapanagiotou-Schenkel I. Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma or leukemia. Klin Padiatr. 2012; 224: 398-403.
24. Stuhmer T, Arts J, Chatterjee M, Borawski J, Wolff A, King P, Einsele H, Leo E and Bargou RC. Preclinical anti-myeloma activity of the novel HDAC-inhibitor JNJ-26481585 Br J Haematol. 2010; 149: 529-536.
25. Heinicke U and Fulda S. Chemosensitization of rhabdomyosarcoma cells by the histone deacetylase inhibitor SAHA. Cancer Lett. 2014; 351: 50-58.
26. Unland R, Clemens D, Heinicke U, Potratz JC, Hotfilder M, Fulda S, Wardelmann E, Fruhwald MC and Dirksen U. Suberoylanilide hydroxamic acid synergistically enhances the antitumor activity of etoposide in Ewing sarcoma cell lines. Anticancer Drugs. 2015; 26: 843-851.
27. Keshelava N, Houghton PJ, Morton CL, Lock RB, Carol H, Keir ST, Maris JM, Reynolds CP, Gorlick R, Kolb EA, Wu J and Smith MA. Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program. Pediatr Blood Cancer. 2009; 53: 505-508.
28. Fulda S, Sieverts H, Friesen C, Herr I and Debatin KM. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res. 1997; 57: 3823-3829.
29. Hacker S, Dittrich A, Mohr A, Schweitzer T, Rutkowski S, Krauss J, Debatin KM and Fulda S. Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8. Oncogene. 2009; 28: 3097-3110.